Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

Daniel Lavanchy

DOI:10.1046/j.1365-2893.2003.00487.x

Corpus ID: 163757

Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

@article{Lavanchy2004HepatitisBV,
  title={Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures},
  author={Daniel Lavanchy},
  journal={Journal of Viral Hepatitis},
  year={2004},
  volume={11}
}

Daniel Lavanchy

Published 2004

Medicine

Journal of Viral Hepatitis

Summary. Hepatitis B virus (HBV) infection is a serious global health problem, with 2 billion people infected worldwide, and 350 million suffering from chronic HBV infection. The 10th leading cause of death worldwide, HBV infections result in 500 000 to 1.2 million deaths per year caused by chronic hepatitis, cirrhosis, and hepatocellular carcinoma; the last accounts for 320 000 deaths per year [ 1, 2 ]. In Western countries, the disease is relatively rare and acquired primarily in adulthood… CONTINUE READING

View on Wiley

Share This Paper

2,412 Citations

Highly Influencial Citations

147

Background Citations

993

Methods Citations

Results Citations

Topics from this paper.

Explore Further: Topics Discussed in This Paper

Paper Mentions

INTERVENTIONAL CLINICAL TRIAL

A Randomized Controlled Trial on the Efficacy of Tenofovir Disoproxil Fumarate (TDF)-Switch Therapy in Chronic Hepatitis B Patients With Incomplete Response to Entecavir

Currently, five nucleos(t)ide analogs are approved for the treatment of chronic hepatitis B, namely lamivudine, adefovir dipivoxil, telbivudine, entecavir (ETV) and tenofovir disoproxil… Expand

Conditions	Chronic Heptitis B
Intervention	Drug

Chinese University of Hong Kong

August 2013 - January 2017

INTERVENTIONAL CLINICAL TRIAL

Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection

Randomized open-label substudy of daily Myrcludex B (MXB) plus pegylated interferon-alpha-2a (PEG-INF-a) in patients with hepatitis B e antigen (HBeAg) negative chronic hepatitis B virus… Expand

Conditions	Chronic Hepatitis D Infection
Intervention	Drug

Hepatera Ltd.

February 2014 - January 2016

INTERVENTIONAL CLINICAL TRIAL

Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.

Conditions	Chronic Hepatitis B
Intervention	Drug

Hepatera Ltd.

November 2012 - October 2014

OBSERVATIONAL CLINICAL TRIAL

Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection

Background: - Hepatitis B and hepatitis C can cause liver damage. They can also cause serious illness, including liver cancer, and even death. This study will follow people who… Expand